Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design
Latest News
May 22, 2013
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe...
Feb 11, 2013
Prosonix Appoints Cécile Miles as Chief Business Officer
Jan 7, 2013
Prosonix Receives £1.3M Grant Award from the Biomedical Catalyst to Accelerate Development of...
Events
18-19 Jun 2013
London, UK